On November 27, 2022 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) reported that it has entered into an evaluation and option agreement with ADC Therapeutics SA (Press release, Biocytogen, NOV 27, 2022, View Source [SID1234624461]). Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. Biocytogen reserves all global rights for these antibodies beyond ADC development. Biocytogen will receive an upfront payment. For each option exercised, Biocytogen will be entitled to an option-exercise fee, and development and commercial milestone payments, which potentially total tens of millions of US dollars, as well as single-digit royalties on net sales.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, Biocytogen will provide ADC Therapeutics with monoclonal and/or biparatopic antibodies directed against three tumor targets, generated through Biocytogen’s Project Integrum (also called RenMiceTM HiTS Platform). ADC Therapeutics will carry out feasibility studies and be responsible for further development and commercialization of the ADC products if the company exercises an option.

"ADC Therapeutics is a leader in the development and commercialization of ADCs. We believe this collaboration with ADC Therapeutics will underscore the value of Biocytogen’s proprietary antibody discovery and screening platforms," said Dr. Yuelei Shen, President and CEO of Biocytogen. "We’ve been dedicated to expanding the possibilities of antibody-based therapeutics in disease treatment, through the exploration of new types of targets and modalities through Project Integrum. The combination of Biocytogen’s strength in antibody development with ADC Therapeutics’ expertise and track record in payload and linker technology may lead to the generation of novel ADC medicines for unmet medical needs in the future."

"We are pleased to enter this collaboration with Biocytogen as we continue expanding our toolbox to realize the full potential of our ADC platform," said Patrick van Berkel, PhD, Chief Scientific Officer of ADC Therapeutics. "We look forward to evaluating the fully human antibodies from Biocytogen’s proprietary discovery platform, which have the potential to accelerate the development of our novel ADCs."

On November 25, 2022 (the "Funding Date"), OncoSec Medical Incorporated (the "Company") reported entered into a Convertible Promissory Note and Security agreement with Grand Decade Developments Limited, a British Virgin Islands limited company and a wholly owned subsidiary of Grand Pharmaceutical Group Limited ("GDDL"), pursuant to which the Company issued a Secured Convertible Promissory Note (the "Note") to GDDL (Filing, 8-K, OncoSec Medical, NOV 25, 2022, View Source [SID1234624535]). The Note has a principal amount of $2,000,000, bears interest at a rate of 5% per annum until November 25, 2023 and 10% per annum thereafter (the "Interest Rate") and matures on November 25, 2024 (the "Maturity Date"), on which date the principal balance and all accrued interest under the Note shall be due and payable. The Interest Rate will be 10% per annum upon occurrence of an event of default, including, but not limited to, the failure by the Company to make payment of principal or interest due under the Note on the Maturity Date, and any commencement by the Company of a case under any applicable bankruptcy or insolvency laws. The principal and interest accrued on the Note may be prepaid without any further agreement of the parties to the Note, or converted (as described below) upon the agreement of the parties to the Note, at any time without penalty to the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Subject to the consent of GDDL, the Note is convertible into such number of fully paid and non-assessable shares of the Company’s common stock, par value $0.0001 per share (the "Common Stock"), into such number of fully paid and non-assessable shares of Common Stock as determined by dividing (i) any portion of the unpaid principal and accrued interest of the Note then outstanding by (ii) the greater of (a) the last closing bid price of a share of Common Stock as reported on the Nasdaq Capital Market ("Nasdaq") on the date the Company and GDDL agree to such conversion and (b) the average closing bid price of a share of Common Stock as reported on Nasdaq for the thirty trading days immediately preceding such date, subject to a share cap of 360,769 shares of Common Stock (the "Share Cap"), representing 19.99% of the total issued and outstanding shares of Common Stock as of November 25, 2022.

Additionally, if at any time after the Funding Date the last closing bid price of a share of Common Stock as reported on the Nasdaq for ten consecutive trading days or the average closing bid price of a share Common Stock as reported on Nasdaq for the thirty trading days immediately preceding such date is equal to or exceeds $44.00 (subject to any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other substantially similar transaction), GDDL may require that the Company prepay the Note through conversion of the then outstanding principal and/or any accrued interest thereon into shares of Common Stock, in whole or in part.

The unpaid principal of and any accrued interest on the Note constitute unsubordinated obligations of the Company and are senior and preferred in right of payment to all equity securities of the Company outstanding as of the Funding Date, which are secured by all of the Company’s right, title and interest, in and to certain of the Company’s intellectual property rights in Hong Kong, Taiwan, China and South Korea, as specified in the Note; provided, however, that the Company may incur or guarantee additional indebtedness after the Funding Date, whether such indebtedness are senior, pari passu or junior to the obligations under the Note.

The foregoing description of the Note is qualified in its entirety by reference to the full text of such Note, a copy of which is attached hereto as exhibits 10.1, and incorporated herein by reference.

On November 25, 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") reported that launched a new dedicated area on its website (www.nordicnanovector.com) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics ("APIM") (Press release, Nordic Nanovector, NOV 25, 2022, View Source [SID1234624429]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new area includes a recording of the webcast and Question & Answer session, which was held for interested parties, including shareholders, on 24 November. During the webcast, shareholders were provided with a more-detailed presentation of the proposed merger with APIM and were given the opportunity to ask their specific questions regarding the merger plans.

Malene Brondberg, Interim CEO and CFO of Nordic Nanovector, says: "We are happy that so many shareholders attended the webcast we hosted yesterday, where we provided more background on the proposed merger with APIM Therapeutics. After a week of highly productive meetings between the Nordic Nanovector and APIM teams, our confidence in a merged company is even stronger than before. Our largest shareholder Folketrygdfondet confirms that it supports the Board’s proposal. We are certain that there is no better alternative, and we encourage all shareholders to vote in favour of the merger proposal."

The proposed merger, which is backed by the Boards of Directors of both companies, is the result of an extensive review conducted by Nordic Nanovector in conjunction with Carnegie Investment Bank ("Carnegie") that explored a range of strategic options for the Company. This review included carefully evaluating a potential stand-alone strategy for Nordic Nanovector, which was deemed not to be a viable option by the Board.

After evaluating 25 possible merger and acquisition opportunities, the Company determined that the merger transaction with APIM represents the best and most exciting opportunity for all of Nordic Nanovector’s shareholders given, among other things, the significant and broad potential of ATX-101, a novel anti-cancer peptide currently in Phase 2 trials. In addition, the combined company will have the discovery and development expertise to potentially generate multiple value-enhancing new drug candidates from its technology platforms.

How to register for the general meeting

Shareholders wishing to attend the general meeting must register no later than 29 November 2022 at 16:00 hours (CET). Shareholders can attend in person, by proxy or by casting advance votes. The deadline is the same for proxies and advance votes as personal attendance. Until the deadline, votes already cast may be changed or withdrawn.

Electronic registration of attendance, proxies and advance voting is easily available through the link posted at the Company’s website: www.nordicnanovector.com. An individual ref. no. and PIN-code required to access the service have been sent to all shareholders with known address.

Registration of personal attendance and proxies can also be made by mail to Nordea Bank Abp, Norwegian branch, Issuer Services, P.O. Box 1166 Sentrum, N-0107 Oslo, Norway, or e-mail to: [email protected] within the deadline. No ref. no. and PIN-code is required for registration by mail or e-mail.

The form of registration of attendance (in person or by proxy) is attached with the notice as made available on Nordic Nanovector’s website and on the company’s ticker on newsweb.no

Advisers

Carnegie Investment Bank is acting as financial advisor to Nordic Nanovector. Advokatfirmaet Selmer AS is acting as legal advisor to Nordic Nanovector and KPMG AS assisted Nordic Nanovector with financial due diligence and a fairness opinion of the exchange ratio.

Advokatfirmaet Schjødt AS is acting as legal advisor to APIM. The valuation of APIM Therapeutics was conducted by Venture Valuation AG, which has now agreed to be identified.

On November 25, 2022 Hologic, Inc. (Nasdaq: HOLX) reported that it will exhibit its extensive portfolio of breast and skeletal health products at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec. 1 (Press release, Hologic, NOV 25, 2022, View Source [SID1234624428]). Among the full suite of breast biopsy and surgery solutions will be Hologic’s Affirm Contrast Biopsy software, which will be on display for the first time since becoming commercially available in the United States.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As the global leader in breast imaging, we are committed to addressing the unmet needs of physicians and their patients across the continuum of breast care and we’re eager to engage with industry leaders at this year’s RSNA meeting to share our vision for the future of breast health," said Erik Anderson, President of Hologic’s Breast and Skeletal Health Solutions Division. "We are equally excited to showcase our new Affirm Contrast Biopsy technology, which is a great example of our commitment to physicians and patients in action."

Affirm Contrast Biopsy software allows clinicians to target and acquire tissue samples in lesions identified with I-View Contrast-Enhanced Mammography software. The contrast solution provides healthcare facilities with a viable and attractive alternative to breast MRI, which historically has been used to find and biopsy more elusive lesions, such as those that cannot be seen via mammography or ultrasound. While breast MRI can be time-consuming and costly, contrast technology gives radiologists another option in the mammography suite that addresses these shortcomings.1,2 In a recent clinical study, 98% of patients had an overall positive opinion of their procedure experience with Affirm Contrast Biopsy software.3

RSNA attendees can experience Hologic’s portfolio at Booth 1911 in South Hall Level 3 at McCormick Place in Chicago. In addition to the Affirm Contrast Biopsy software, Hologic will feature its Dimensions mammography portfolio and Supersonic MACH ultrasound systems.

Hologic will also host a series of CME- and non-CME-accredited medical education symposiums and learning opportunities, accessible to attendees on-site and from remote locations. The medical education sessions include:

"Upright Biopsy with Brevera Breast Biopsy System: Real-Time Imaging, Verification & Automated Handling"
Sunday, Nov. 27: 11:45 a.m. – 12:45 p.m. CST
Dr. Krystal Airola will demonstrate new upright breast biopsy technologies that will enhance accuracy, workflow and patient experience. She will share her experiences with the Affirm 2D/3D upright biopsy, lateral arm approach and Brevera Breast Biopsy system, which integrates tissue acquisition, real-time imaging and verification, and post-biopsy sample handling. Dr. Airola will also share cases and explain how to significantly reduce the time and discomfort to patients in the biopsy suite while maximizing biopsy suite efficiencies and clinical decision-making.
"Emerging Ultrasound Technology in Liver Surveillance"
Monday, Nov. 28: 12:00 p.m. – 1:00 p.m. CST
Learn more about the advancements in ultrasound technology with ShearWave Elastography. There are many opportunities to improve workflow efficiencies in liver surveillance that drive superior patient experiences and outcomes. In this lecture, participants will review comparisons with existing and emerging ultrasound technologies and techniques.
"Current AI Applications in Mammography: Focus on Genius AI Detection Software"
Tuesday, Nov. 29: 12:00 p.m. – 1:00 p.m. CST
Attendees will hear from an expert on the benefits of artificial intelligence (AI) in mammography screening. With new high-resolution technologies being implemented, see how AI can reduce dose, file size and reading times. A focus will be on deep-learning AI and the benefits of Genius AI Detection software in clinical decision-making and increasing productivity.
"Panel Discussion: Options in Localization"
Wednesday, Nov. 30: 12:00 p.m. – 1:00 p.m. CST
Join a multidisciplinary conversation on localization. Hear perspectives from leading radiologists and breast surgeons about what they like, what they use and why. What is the role of wires? What other technologies are available? What are the strengths and weaknesses of different options?

On November 25, 2022 IMV Inc. ("IMV" or the "Company") (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, reported that, on November 22, 2022, the Company received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company’s Market Value of Listed Securities ("MVLS") for the last 30 consecutive business days was below the required minimum of US$35 million for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(2) (Press release, IMV, NOV 25, 2022, View Source [SID1234624426]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The notification letter is only a notification of deficiency and has no immediate effect on the listing or trading of IMV’s common shares. The Company will continue to trade on the Nasdaq Capital Market under the symbol "IMV", subject to the Company’s compliance with the other listing requirements. The Company’s common shares are also listed on the Toronto Stock Exchange, and the notification letter does not affect the Company’s compliance status with such listing.

The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until May 22, 2023, in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(C). If at any time before May 22, 2023, the Company’s MVLS closes at or above US$35 million for a minimum of ten consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance under the MVLS requirement, and the matter will be closed. In the event the Company does not regain compliance by May 22, 2023, the Company may face delisting.

The Company’s business operations are not affected by the receipt of the notification letter and the Company fully intends to regain compliance with Nasdaq listing rules. The Company will actively monitor its MVLS and is evaluating all available options to regain compliance with Nasdaq’s continued listing criteria.

Special Meeting of Shareholders

Shareholders are reminded of the upcoming special meeting of shareholders to consider the proposed consolidation of IMV’s total issued and outstanding shares. Two leading independent proxy advisors have issued recommendations for IMV shareholders to vote FOR the proposed share consolidation. The special meeting is being held on December 7, 2022 at 11:00 a.m. (Eastern Time). We encourage you to vote your shares well in advance of the proxy voting deadline on December 5, 2022 at 11:00 a.m. (Eastern Time). For any questions or if you require assistance with voting your shares, please contact our proxy solicitation agent, Laurel Hill Advisory Group at 1-877-452-7184 (North America Toll Free), 416-304-0211 (Calls Outside North America) or by email at [email protected].